您的位置: 首页 > 农业专利 > 详情页

Concurrent chemotherapy and immunotherapy
专利权人:
The Board of Regents of The University of Texas System;Duke University
发明人:
Sampson, John H.,Bigner, Darell D.,Mitchell, Duane,Heimberger, Amy
申请号:
AU2006312013
公开号:
AU2006312013B2
申请日:
2006.11.02
申请国别(地区):
AU
年份:
2012
代理人:
摘要:
The concurrent administration of chemotherapy and immunotherapy has been considered a contraindication because of the concern that the induced lymphopenia would ablate therapeutic efficacy of immunotherapy. Temozolomide has been shown to be an effective chemotherapeutic for patients with malignant gliomas and to deprive patients with glioblastoma (GBM) patients of this agent in order to treat with immunotherapy is controversial. Despite conventional dogma, we demonstrate that both chemotherapy and immunotherapy can be delivered concurrently without negating the effects of immunotherapy, hi fact, the temozolomide induced lymphopenia may actually be synergistic with a peptide vaccine.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充